SK Biopharmaceuticals (KRX:326030) posted a 158% year-over-year jump in net income attributable to owners of the parent to 85.1 billion won from 32.9 billion won for the second quarter.
Sales rose 40% to 247.4 billion won from 176.3 billion won for the three months ended June 30.
Shares of the pharmaceutical company rose 5% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments